Metagenomi Therapeutics (MGX) Share-based Compensation (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Share-based Compensation for 4 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 29.59% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $10.5 million, a 17.68% decrease from a year earlier, with the FY2025 full-year figure at $11.9 million, down 35.58% from the prior year.
• Share-based Compensation was $2.3 million for Q2 2026 at Metagenomi Therapeutics, down from $2.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $30.6 million in Q1 2023 and troughed at $228000.0 in Q4 2023.
• A 4-year average of $4.8 million and a median of $3.1 million in 2025 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 1396.49% in 2024, down 83.48% in 2024.
• Over 4 years, Share-based Compensation stood at $228000.0 in 2023, then soared by 1396.49% to $3.4 million in 2024, then retreated by 21.04% to $2.7 million in 2025, then fell by 15.81% to $2.3 million in 2026.
• The last three Share-based Compensation figures came in at $2.3 million (Q2 2026), $2.6 million (Q1 2026), and $2.7 million (Q4 2025), per Business Quant data.